Clinically proven to reduce attacks with the possibility of zero attacks for periods of time—the only every-2-weeks preventive treatment evaluated in a 2.5-year study^1-5

The 2020 US HAEA guidelines recommend TAKHZYRO as one of the first-line therapies for long-term prophylaxis⁶

HAEA=Hereditary Angioedema Association.